Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT)

Agendia ; Breast International Group ; et al.

In: Mook S, BonnefoH, PrunerG, Larsont D, Jaskwz J, Sabadell MD, MacGrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Day clal practe of fresh tumour tsue freezg and gene expressn profg; logts pot study precedg the MDACT trl. Eur J Cancer. 2009 May;45(7):1201-1208. do 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14. Cardoso F, Van't Veer L, Rutgers E, LoS, Mook S, Pcart-Gebhart MJ. Clal applatn of the 70-gene profe: the MDACT trl. J Cl Oncol. 2008 Feb 10;26(5):729-35. do 10.1200/JCO.2007.14.3222. Cardoso F, Pcart-Gebhart M, Van't Veer L, Rutgers E; TRANSB Consortm. The MDACT trl: the fst prospecte clal valatn of a genom tool. Mol Oncol. 2007 Dec;1(3):246-51. do 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22. Mook S, Van't Veer LJ, Rutgers EJ, Pcart-Gebhart MJ, Cardoso F. dualatn of therapy usg Mammaprt: from development to the MDACT Trl. Cancer Genoms Proteoms. 2007 May-Jun;4(3):147-55. Bogaerts J, Cardoso F, Buyse M, Braga S, LoS, Harron JA, Bes J, Mook S, Decker N, Ravd P, Therasse P, Rutgers E, van 't Veer LJ, Pcart M; TRANSB consortm. Gene snature evaluatn as a prognost tool: challenges the desn of the MDACT trl. Nat Cl Pract Oncol. 2006 Oct;3(10):540-51. do 10.1038/ncponc0591. Viale G, Slaets L, Bogaerts J, Rutgers E, Van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol. 2014 Apr;25(4):816-823. doi: 10.1093/annonc/mdu026. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1. MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes

Online report

Wie komme ich dran?

Zugriff:

View record in ClinicalTrials.gov (Volltext)

Titel:	Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT)
Autor/in / Beteiligte Person:	Agendia ; Breast International Group ; Roche Pharma, AG ; Novartis ; Sanofi
Link:	View record in ClinicalTrials.gov (Volltext) https://www.eortc.org/research_field/clinical-detail/10041/
Quelle:	Mook S, BonnefoH, PrunerG, Larsont D, Jaskwz J, Sabadell MD, MacGrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Day clal practe of fresh tumour tsue freezg and gene expressn profg; logts pot study precedg the MDACT trl. Eur J Cancer. 2009 May;45(7):1201-1208. do 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14. Cardoso F, Van't Veer L, Rutgers E, LoS, Mook S, Pcart-Gebhart MJ. Clal applatn of the 70-gene profe: the MDACT trl. J Cl Oncol. 2008 Feb 10;26(5):729-35. do 10.1200/JCO.2007.14.3222. Cardoso F, Pcart-Gebhart M, Van't Veer L, Rutgers E; TRANSB Consortm. The MDACT trl: the fst prospecte clal valatn of a genom tool. Mol Oncol. 2007 Dec;1(3):246-51. do 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22. Mook S, Van't Veer LJ, Rutgers EJ, Pcart-Gebhart MJ, Cardoso F. dualatn of therapy usg Mammaprt: from development to the MDACT Trl. Cancer Genoms Proteoms. 2007 May-Jun;4(3):147-55. Bogaerts J, Cardoso F, Buyse M, Braga S, LoS, Harron JA, Bes J, Mook S, Decker N, Ravd P, Therasse P, Rutgers E, van 't Veer LJ, Pcart M; TRANSB consortm. Gene snature evaluatn as a prognost tool: challenges the desn of the MDACT trl. Nat Cl Pract Oncol. 2006 Oct;3(10):540-51. do 10.1038/ncponc0591. Viale G, Slaets L, Bogaerts J, Rutgers E, Van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol. 2014 Apr;25(4):816-823. doi: 10.1093/annonc/mdu026. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1. MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes
Medientyp:	report
Sonstiges:	Nachgewiesen in: ClinicalTrials.gov Sprachen: English

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.